Stifel Reiterates Buy Rating on Immunovant (IMVT), expects the stock to trade higher on IMVT-1402 data
Tweet Send to a Friend
Stifel analyst Alex Thompson reiterated a Buy rating and $34.00 price target on Immunovant (NASDAQ: IMVT), following the company's report ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
